fasudil has been researched along with Fabry Disease in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Fabry Disease: An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JB | 1 |
| Seol, DW | 1 |
| Do, HS | 1 |
| Yang, HY | 1 |
| Kim, TM | 1 |
| Byun, YG | 1 |
| Park, JM | 1 |
| Choi, J | 1 |
| Hong, SP | 1 |
| Chung, WS | 1 |
| Suh, JM | 1 |
| Koh, GY | 1 |
| Lee, BH | 1 |
| Wee, G | 1 |
| Han, YM | 1 |
1 other study available for fasudil and Fabry Disease
| Article | Year |
|---|---|
Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease.
Topics: alpha-Galactosidase; Animals; Endothelial Cells; Enzyme Replacement Therapy; Fabry Disease; Mice; Ph | 2023 |